AML
Article
Alvocidib followed by cytarabine and mitoxantrone shows clinical activity in MCL-1-dependent R/R AML
Article
ICH affects survival in nonpromyelocytic AML patients receiving intensive chemotherapy
Article
Antimicrobial prophylaxis prevents life-threatening infections in children with AML receiving chemotherapy
Article
New insights on OCV-501 induced immune response and survival in elderly AML patients in CR1
Article
Newly diagnosed AML: Optimization of idarubicin and cytarabine induction based on D5-PBCR
Article
RIC transplant improves survival in older AML patients
Article
AML: Similar posttransplant short-term outcomes after azacitidine-venetoclax vs. intensive chemotherapy
Article
Outpatient neutropenia management appears possible without excess risk in pediatric AML
Article
Newly diagnosed mutant-IDH2 AML: Enasidenib + azacitidine fares better than azacitidine in phase 2
Latest News
New trials in leukemia: Could your patient benefit?
Late-phase trials are opening up for leukemia patients aged 1-65 years.